Tianjin Pharmaceutical Da Ren Tang Group (T14) Fair Value & Analysis
Healthcare · SG · Market cap $3.6B
Fair value as of: Jul 4, 2026
From 22 valuation models · updated today
Share price −12.1% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.6578 – $3.66 · fair‑value band $1.51 – $2.46 · the $2.77 price screens above the $1.98 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Tianjin Pharmaceutical Da Ren Tang Group (T14) currently trades at $2.77, while our model-based Fair Value estimate is $1.98 — implying the stock looks roughly 28.5% overvalued today. We read business quality at 65/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Tianjin Pharmaceutical Da Ren Tang Group generated revenue of $5.0B at a net margin of 43.8%. Revenue grew 4.1% year over year. It earns a return on equity of 27.5%. The stock trades on a trailing P/E of 6.6. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. The company was founded in 1915 and is based in Tianjin, the People's Republic of China.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Tianjin Pharmaceutical Da Ren Tang Group reported revenue of $4.9B in FY2025 versus $6.9B in FY2021, a compound −8.1%/yr. Reported net income was $2.1B in FY2025, compounding +29.0%/yr from FY2021.
Is T14 fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Tianjin Pharmaceutical Da Ren Tang Group (T14) undervalued?
What is the fair value of T14?
What is the quality score of T14?
What is the revenue of Tianjin Pharmaceutical Da Ren Tang Group (T14)?
What is the net profit margin of T14?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.